The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis

Respiratory Investigation

Volumn 51, Issue 3, 2013, Pages 175-183

  Ando, Katsutoshi ^a,f   Kurihara, Masatoshi ^b,f   Kataoka, Hideyuki ^b,f   Ueyama, Masako ^c   Togo, Shinsaku ^a   Sato, Teruhiko ^a,f   Doi, Tokuhide ^d   Iwakami, Shin ichiro ^e   Takahashi, Kazuhisa ^a   Seyama, Kuniaki ^a,f   Mikami, Masashi ^c  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d Fukuoka Clinic   (Japan)

^e JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^f Study Group of Pneumothorax and Cystic Lung Diseases   (Japan)

Author keywords

Chylous effusion; Lymphangioleiomyomatosis; MTOR inhibitor; Sirolimus

Indexed keywords

RAPAMYCIN;

ADULT; ARTICLE; ASPERGILLOSIS; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HUMAN; JAPANESE; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; LYMPHANGIOLEIOMYOMATOSIS; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; STOMACH DISCOMFORT; STOMATITIS; THORAX RADIOGRAPHY; UPPER RESPIRATORY TRACT INFECTION;

CHYLOUS EFFUSION; LYMPHANGIOLEIOMYOMATOSIS; MTOR INHIBITOR; SIROLIMUS;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; CHYLOTHORAX; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG NEOPLASMS; LYMPHANGIOMYOMA; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PLEURAL EFFUSION, MALIGNANT; RETROSPECTIVE STUDIES; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84882833554     PISSN: 22125345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resinv.2013.03.002     Document Type: Article

References (20)

1. Corrin B., Liebow A.A., Friedman P.J. Pulmonary lymphangiomyomatosis. A review. Am J Pathol 1975, 79:348-382.
2. Carrington C.B., Cugell D.W., Gaensler E.A., et al. Lymphangioleiomyomatosis. Physiologic-pathologic-radiologic correlations. Am Rev Respir Dis 1977, 116:977-995.
3. Astrinidis A., Khare L., Carsillo T., et al. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet 2000, 37:55-57.
4. Carsillo T., Astrinidis A., Henske E. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000, 97:6085-6090.
5. Sato T., Seyama K., Fujii H., et al. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 2002, 47:20-28.
6. Van Slegtenhorst M., de Hoogt R., Hermans C., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277:805-808.
7. Consortium TECTS Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993, 75:1305-1315.
8. Povey S., Burley M.W., Attwood J., et al. Two loci for tuberous sclerosis: one on 9q34 and one on 16p13. Ann Hum Genet 1994, 58:107-127.
9. Sengupta S., Peterson T.R., Sabatini D.M. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010, 40:310-322.
10. Bissler J.J., McCormack F.X., Young L.R., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008, 358:140-151.
11. McCormack F.X., Inoue Y., Moss J., et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011, 364:1595-1606.
12. Ohara T., Oto T., Miyoshi K., et al. Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis. Ann Thorac Surg 2008, 86:e7-e8.
13. Peces R., Cuesta-López E., Peces C., et al. Giant bilateral renal angiomyolipomas and lymphangioleiomyomatosis presenting after two successive pregnancies successfully treated with surgery and rapamycin. Sci World J 2011, 11:2115-2123.
14. Hayashida M., Seyama K., Inoue Y., et al. Criteria for designation of lymphangioleiomyomatosis in the Specified Disease Treatment Research Program. Nihon Kokyuki Gakkai Zasshi 2011, 49:67-74. [article in Japanese].
15. Seyama K., Kumasaka T., Souma S., et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 2006, 4:143-152.
16. Taveira-DaSilva A.M., Hathaway O., Stylianou M., et al. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 2011, 154:797-805.
17. Davies D.M., de Vries P.J., Johnson S.R., et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: A phase 2 trial. Clin Cancer Res 2011, 17:4071-4081.
18. Makino Y., Shimanuki Y., Fujiwara N., et al. Peritoneovenous shunting for intractable chylous ascites complicated with lymphangioleiomyomatosis. Internal Med 2008, 47:281-285.
19. Moua T., Olson E.J., Jean H.C., et al. Resolution of chylous pulmonary congestion and respiratory failure in LAM with sirolimus therapy. Am J Respir Crit Care Med 2012, [Epub ahead of print].
20. Inoue Y., McCormack F.X., Lee H.S., et al. The MILES Trial: the effect of Asian race on outcomes in patients with lymphangioleiomyomatosis. Am J Respir Crit Care Med 2012, 185:A4444.